CIRM Pursues “Prudent Path” Forward with Genome Editing Technologies
By Jonathan Thomas,
The Stem Cellar
| 06. 01. 2015
Untitled Document
CIRM’s mission is to accelerate the delivery of stem cell treatments to patients with unmet medical needs. In pursuit of this mission CIRM consistently supports studies designed to apply the latest advances in research and medicine. For example, CIRM has supported the development some of the first therapies utilizing human embryonic stem cells. Another example where advanced methods are being employed are clinical trials for HIV/AIDS. In this example, the treatment utilizes genome-editing technology to make the patient’s immune system resistant to infection.
Genome editing has attracted considerable attention since a report of this technology being used to modify human embryos was recently published. Reports of embryo editing have prompted concerns that it may be used to permanently alter our genetic heritage, and have resulted in a broad consensus that there is a need for open discussion of the merits and risks of these technologies by a range of participants – scientists, clinicians, social scientists, the general public, and relevant public entities and interest groups.
CIRM has consistently sought to address, in a comprehensive and...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...